Bausch Health Files Patent Infringement Lawsuit Against Norwich Pharmaceuticals

Bausch Health Companies Inc., along with its Salix Pharmaceuticals unit, announced the filing of a patent infringement lawsuit against Norwich Pharmaceuticals, Inc. The case was lodged in the U.S. District Court for the District of New Jersey.

The lawsuit follows Norwich's submission of an amendment to its Abbreviated New Drug Application (ANDA) to the FDA. Norwich seeks approval to market a generic version of XIFAXAN® 550 mg, used to treat irritable bowel syndrome with diarrhea (IBS-D).

Bausch Health previously won a lawsuit in August 2022 preventing Norwich's first ANDA for XIFAXAN® until October 2029. Recent patents acquired by Bausch Health further protect XIFAXAN® 550 mg and its use for IBS-D. Bausch Health remains committed to defending its intellectual property and ensuring patient safety.